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Abstract
Background: Molecular breast imaging (MBI) is a functional test used for supplemental screening of women with
mammographically dense breasts. Additionally, MBI depicts variable levels of background parenchymal uptake (BPU)
within nonmalignant, dense fibroglandular tissue. We investigated whether BPU is a risk factor for breast cancer.
Methods: We conducted a retrospective case-control study of 3027 eligible women who had undergone MBI
between February 2004 and February 2014. Sixty-two incident breast cancer cases were identified. A total of 179
controls were matched on age, menopausal status, and MBI year. Two radiologists blinded to case status independently
assessed BPU as one of four categories: photopenic, minimal to mild, moderate, or marked. Conditional logistic regression
analysis was performed to estimate the associations (OR) of BPU categories (moderate or marked vs. minimal to mild or
photopenic) and breast cancer risk, adjusted for other risk factors.
Results: The median age was 60.2 years (range 38–86 years) for cases vs. 60.2 years (range 38–88 years) for
controls (p = 0.88). Women with moderate or marked BPU had a 3.4-fold (95 % CI 1.6–7.3) and 4.8-fold (95 % CI
2.1–10.8) increased risk of breast cancer, respectively, compared with women with photopenic or minimal to mild
BPU, for two radiologists. The results were similar after adjustment for BI-RADS density (OR 3.3 [95 % CI 1.6–7.2]
and OR 4.6 [95 % CI 2.1–10.5]) or postmenopausal hormone use (OR 3.6 [95 % CI 1.7–7.7] and OR 5.0 [95 % CI
2.2–11.4]). The association of BPU with breast cancer remained in analyses limited to postmenopausal women
only (OR 3.8 [95 % CI 1.5–9.3] and OR 4.1 [95 % CI 1.6–10.2]) and invasive breast cancer cases only (OR 3.6 [95 %
CI 1.5–8.8] and OR 4.4 [95 % CI 1.7–11.1]). Variable BPU was observed among women with similar mammographic
density; the distribution of BPU categories differed across density categories (p < 0.0001).
Conclusions: This study provides the first evidence for BPU as a risk factor for breast cancer. Among women with
dense breasts, who comprise >40 % of the screening population, BPU may serve as a functional imaging biomarker to
identify the subset at greatest risk.
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Background
Mammographic density is known to be an important
factor in reducing the sensitivity of mammography
[1, 2]. Therefore, supplemental screening options capable
of detecting mammographically occult cancers are now
increasingly being offered to women with dense breasts
[3–5]. Density is also strongly associated with breast can-
cer risk, even after accounting for its masking of cancers
[1, 6]. However, density alone lacks sufficient discrimin-
atory accuracy to be clinically useful in individual risk
assessment [6, 7]. Risk models developed within the Breast
Cancer Surveillance Consortium (BCSC) have incorpo-
rated American College of Radiology (ACR) Breast
Imaging-Reporting and Data System (BI-RADS) breast
density categories [8], a genetic risk score, and history
of benign breast disease; yet, c-statistics, or AUC, re-
main <0.67 [9, 10]. Given the high prevalence of dense
breasts (43 % of screening-eligible U.S. women have
heterogeneously or extremely dense breasts according
to BI-RADS criteria [11]), coupled with increasing adop-
tion of breast density notification laws (in 26 states to date
[12]), further tools are needed to identify women most
likely to benefit from supplemental screening or primary
prevention.
Molecular breast imaging (MBI) is a functional im-
aging technique that uses a specialized gamma camera
to detect preferential uptake of Tc-99m sestamibi in
metabolically active breast tissue. When used as a sup-
plement to screening mammography in women with
dense breasts, MBI showed an incremental cancer detec-
tion rate of 8.8 per 1000 women screened [5]. MBI can
also show variable levels of radiotracer uptake within
areas of nonmalignant fibroglandular tissue, a finding
termed background parenchymal uptake (BPU) [13]. BPU
is associated with hormonal influences, including meno-
pausal status, postmenopausal hormone use, and phase of
menstrual cycle [14, 15]. Also, BPU varies among women
with similar mammographic density [14].
We hypothesized that the functional differences reflected
in MBI background provide additional information for
determining breast cancer risk in women with dense
breasts. Here, our objective was to investigate whether
BPU on MBI is a risk factor for breast cancer.
Methods
Study population
We performed a retrospective case-control study that
was compliant with the U.S. Health Insurance Portability
and Accountability Act and approved by the Mayo
Clinic Institutional Review Board, which issued a waiver
of informed consent. Our institutional MBI database was
reviewed to identify all patients (n = 3202) who had had at
least one MBI examination performed at the Mayo Clinic
in Rochester, MN, USA, between 1 February 2005 and 28
February 2014. The Mayo Clinic patients provides a gen-
eral authorization for use of medical record information
for research purposes. We included only women who pro-
vided this authorization (n = 3085 [96 %] of 3202). For
women who had had multiple MBI examinations per-
formed, data from the earliest (index) MBI were used
for analysis. Follow-up for breast cancer through December
2014 was conducted through review of medical records and
linkage to the Mayo Clinic Tumor Registry.
Women with breast implants at the time of index MBI
were excluded, as photopenia due to the presence of im-
plants makes assessment of BPU difficult. Women with
a history of breast cancer before the index MBI examin-
ation or a diagnosis within 180 days following the index
MBI were also excluded to minimize prevalent cases, as
done in prior studies [16]. After these exclusions, 3027
eligible participants remained from among whom to iden-
tify cases and controls. Average follow-up time of partici-
pants was 4.6 years.
Incident cases were defined as participants with a
histopathologic diagnosis of ductal carcinoma in situ
(DCIS) or invasive carcinoma in either breast at least
180 days after the index MBI. Sixty-two incident breast
cancer cases were identified. The median time be-
tween index MBI examination and cancer diagnosis
was 3.1 years (IQR 1.5–4.2 years). Fifty-eight (94 %) of
sixty-two cases were diagnosed more than 1 year after
the index MBI.
Up to three control subjects per case (n = 179) were
selected from among the 2965 women who were not di-
agnosed with breast cancer over the study period, with
matching to cases on age (within 5 years), menopausal
status (exact), and year of MBI (within 1 year). Matched
controls were required to be followed for at least as long
as matched cases and to have had negative findings on
all subsequent breast imaging performed at our institution
over the corresponding follow-up time. Median follow-up
time for controls was 6.1 years (IQR 3.7–7.8 years).
Of the 241 women studied, MBI was performed as a sup-
plemental screen to mammography in 228 (95 %, compris-
ing 57 cases and 171 controls). In the remaining 13 women
(5 %), MBI was performed for further evaluation of the fol-
lowing: breast mass initially detected on mammography or
ultrasound (three cases, five controls), recent histopatho-
logic diagnosis of atypia or lobular carcinoma in situ (one
case, two controls), bloody nipple discharge (one case), and
breast pain (one control).
Covariate information, including body mass index
(BMI), menopausal status, postmenopausal hormone
use, breast biopsy history, and family history of breast
cancer was obtained primarily in a prospective manner
through questionnaires and medical record review
performed at the time of the MBI examination. We
examined only those factors previously shown to be
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associated with BPU [14]. Missing information was
retrospectively abstracted by research nurses.
Molecular breast imaging procedure
MBI examinations were performed using one of two dedi-
cated dual-head gamma camera systems equipped with
cadmium zinc telluride detectors (LumaGEM, Gamma
Medica, Salem, NH, USA; or Discovery NM750b, GE
Healthcare, Haifa, Israel). Patients received an intravenous
injection of Tc-99m sestamibi in an arm vein. Before June
2009, MBI examinations were performed with adminis-
tered doses of 740 MBq of Tc-99 m sestamibi. Changes to
the MBI detectors’ collimation, system energy window set-
tings, and radiopharmaceutical injection techniques over
the course of the study period resulted in an approxi-
mately threefold gain in the number of counts that could
be collected during an MBI examination, such that we
were able to lower the administered dose to patients pro-
portionally while preserving count density and image
quality [17, 18]. In June 2009 and later, the administered
dose was between 240 and 300 MBq of Tc-99m sestamibi.
Matching of cases and controls by year of MBI served to
control for any changes in MBI examinations before and
after the protocol change.
Imaging commenced approximately 5 minutes after in-
jection. Bilateral views in craniocaudal and mediolateral
oblique-analogous projections were acquired for 10 mi-
nutes per view, with the breast under light compression to
limit patient motion. All study participants had bilateral
MBI examinations.
Background parenchymal uptake assessment
MBI examinations were retrospectively reviewed by two
breast imaging radiologists with 6 and 10 years of ex-
perience, respectively, in MBI interpretation. Readers
interpreted BPU independently while blinded to the
participants’ case status. BPU was qualitatively assessed
per breast according to a validated lexicon for gamma
imaging of the breast as one of four categories: photo-
penic, minimal to mild, moderate, or marked (Fig. 1)
[19]. These categories describe the relative intensity of
radiotracer uptake observed in areas of normal paren-
chyma compared with that in areas of subcutaneous fat,
as follows: photopenic BPU, parenchymal intensity less
than fat intensity; minimal to mild BPU, parenchymal
intensity equal to or slightly greater than fat intensity;
moderate BPU, parenchymal intensity greater than mild
but less than twice as intense as fat; and marked, paren-
chymal intensity greater than twice fat intensity.
Mammographic density assessment
Mammographic density was assessed on mammograms ob-
tained closest to the time of MBI. Mammograms were avail-
able for 232 (96 %) of 241 subjects. Most mammograms
were obtained within 21 days of MBI (223 [96 %] of 232).
Six were obtained within 6 months, and the remaining three
were obtained within 14 months of MBI. During the course
of routine clinical practice, mammographic density was
subjectively assessed according to ACR BI-RADS dens-
ity categories (fourth edition) by breast imaging radiol-
ogists [8]. Density was also quantitatively assessed as
percentage density by a trained operator using semiauto-
mated software (Cumulus; University of Toronto, Toronto,
ON, Canada [20]) as previously described [14, 21]. Percent-
age density was measured on right and left craniocaudal
mammograms from either digitized film or “for presenta-
tion” digital mammograms in Digital Imaging and Commu-
nications in Medicine format.
Statistical analysis
Case and control characteristics are presented as mean,
SD, and range for continuous variables and frequency
and percentage for categorical variables. Conditional lo-
gistic regression analysis was performed to test for dif-
ferences between cases and controls and to estimate the
associations of BPU categories and risk of breast cancer
with adjustments for covariates. Exploratory analyses were
also repeated within premenopausal and postmenopausal
subgroups and in a subgroup limited to invasive breast
cancer cases. Further, we performed analyses on data from
before and after June 2009 to examine whether changes in
MBI protocol influenced the results. To measure the
discriminatory ability of the models, the AUC for BPU
discrimination was calculated within case-control sets
to match the design.
Analysis was performed by first considering BPU as a
four-category variable, using the category “minimal to
mild” as a reference group because this was the largest
group and provided a more stable relative risk estimate.
Tests for trend were examined by including BPU as an
ordinal variable in the conditional logistic regression
model. Analysis was also performed considering BPU
as a dichotomous variable by combining categories of
“photopenic” with “minimal to mild” and “moderate”
with “marked.”
The maximum BPU was used in participants whose
BPU assessment differed between breasts, similarly to
how clinical assessment of BI-RADS density is done [8].
To assess whether the associations were different for
BPU assessed on contralateral vs. ipsilateral breasts, ana-
lyses were also done stratified by side as defined by can-
cer location. For this analysis, the side of the matched
case was used to define the side for controls.
Interreader agreement in BPU assessment was summa-
rized by the weighted κ statistic. κ values were inter-
preted as ≤0.20 or less, poor; 0.21–0.40, fair; 0.41–0.60,
moderate; 0.61–0.80, good; and 0.81–1.00, very good
agreement [22].
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The χ2 test was used as appropriate to test for differences
in distribution of BPU categories across BI-RADS density
categories. For all comparisons, p < 0.05 was considered sta-
tistically significant. Analyses were performed using SAS
software version 9.4 (SAS Institute, Cary, NC, USA).
Results
Study group characteristics
Characteristics of breast cancer cases and matched con-
trols are shown in Table 1. As expected, cases and controls
were similar on matched variables of age and menopausal
status. Nearly all subjects (174 [97 %] of 179) were age-
matched exactly; the remaining five subjects were age-
matched within 1–3 years. Breast cancer cases had higher
percentages of family history, history of atypia or lobular
carcinoma in situ, mean BMI, Gail model 5-year risk, and
BCSC model 5-year risk, but none of these reached statis-
tical significance.
Of the 62 incident breast cancer cases, 45 (73 %) were
invasive and 17 (27 %) were DCIS. Images from an
example breast cancer case are given in Fig. 2. Details of
cases are given in Additional file 1: Table S1.
BPU agreement
When BPU was considered as a four-category ordinal vari-
able, interreader agreement was good (κ= 0.77, 95 % CI
0.70–0.84) with 85 % (205 of 241) agreement. When BPU
was considered as a dichotomous variable, interreader agree-
ment was good to very good (κ= 0.82, 95 % CI 0.74–0.92)
with 94 % (227 of 241) agreement. BPU differed between
Fig. 1 Examples of background parenchymal uptake categories. Molecular breast imaging (MBI) examinations and corresponding full-field digital
mammograms from four different women are shown. All images were acquired in the mediolateral oblique projection. MBI with photopenic background
parenchymal uptake (BPU) (a) and corresponding mammogram (b). MBI with minimal to mild BPU (c) and corresponding mammogram (d). MBI with
moderate BPU (e) and corresponding mammogram (f). MBI with marked BPU (g) and corresponding mammogram (h)
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breasts in 10 (4 %) of 241 participants (5 cases, 5 controls)
for reader 1 and in 24 (10 %) of 241 participants (10 cases,
14 controls) for reader 2.
Breast cancer cases vs. controls
BPU level using either categorization was associated with
breast cancer risk. When BPU was considered as a four-
category variable, the BMI-adjusted OR increased with in-
creasing BPU (Table 2). For reader 1, the OR increased
from 0.8 for photopenic BPU to 3.0 for marked BPU (p-
trend = 0.007). For reader 2, the OR increased from 0.5 for
photopenic BPU to 6.2 for marked BPU (p-trend < 0.001).
When we considered BPU as a dichotomous vari-
able, we found that women with moderate or marked
BPU had a greater risk of incident breast cancer than
women with photopenic or minimal to mild BPU. For
the two readers, the BMI-adjusted ORs for moderate
or marked BPU vs. photopenic or minimal to mild
BPU was 3.4 (95 % CI 1.6–7.3) and 4.8 (95 % CI 2.1–
10.8) (Table 3). When the dataset was limited to inva-
sive breast cancer cases and respective matched
controls, the results were similar: BMI-adjusted ORs
were 3.6 (95 % CI 1.5–8.8) and 4.4 (95 % CI 1.7–
11.1) for the two readers.
Table 1 Characteristics of breast cancer cases and controls, matched on age, menopausal status, and MBI year
Characteristic Breast cancer cases (n = 62) Controls (n = 179) p value
Age at MBI,ayears 60.3 ± 10.6 (38–86) 60.2 ± 10.6 (38–88) 0.88
Menopausal status N/Ab
Premenopausal 13 (21) 38 (21)
Postmenopausal 49 (79) 141 (79)
BMIa 27.7 ± 6.4 (18.8–55.5) 26.2 ± 4.6 (18.6–44.3) 0.08
Postmenopausal systemic HRTc 0.57
Current use at MBI 13 (27) 44 (31)
No current use at MBI 36 (73) 97 (69)
BI-RADS density 0.77
Almost entirely fat 1 (2) 3 (2)
Scattered fibroglandular densities 10 (16) 34 (19)
Heterogeneously dense 44 (71) 114 (64)
Extremely dense 7 (11) 26 (15)
Unknown 0 2 (1)
Percentage densitya 24.8 ± 8.3 (3.5–48.0) 24.6 ± 10.2 (1.8–53.8) 0.92
MBI protocol 0.88
740 MBq Tc-99m sestamibi 36 (58) 102 (57)
240–300 MBq of Tc-99m sestamibi 26 (42) 77 (43)
Tumor invasiveness
Invasive 45 (73) NA
DCIS 17 (27) NA
Gail model 5-year riska 2.7 ± 1.5 (0.6–7.2) 2.4 ± 1.5 (0.5–9.5) 0.23
BCSC model 5-year riska 2.6 ± 1.2 (0.7–5.4) 2.3 ± 1.5 (0.4–13.2) 0.29
Family history of breast cancer 0.45
One or more first-degree relatives 33 (53) 86 (48)
No first-degree relatives 29 (47) 93 (52)
Personal history of biopsy showing atypia or LCIS 0.07
Yes 6 (10) 6 (3)
No 56 (90) 173 (97)
BCSC Breast Cancer Surveillance Consortium, BI-RADS Breast Imaging-Reporting and Data System, BMI body mass index, DCIS ductal carcinoma in situ, HRT hormone
replacement therapy, LCIS lobular carcinoma in situ, MBI molecular breast imaging
Note: Unless otherwise noted, data are number of patients and data in parentheses are percentages
aData are mean ± SD. Data in parentheses are ranges.
bExact matches
cData are among postmenopausal women only (49 breast cancer cases, 141 controls)
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Neither BI-RADS density nor percentage density was sta-
tistically significantly associated with breast cancer in this
study (BI-RADS ordinal OR 1.2, 95 % CI 0.7–2.0; percent-
age density OR [per 1 SD in square root of percentage
density] 1.2, 95 % CI 0.8–1.8) (Table 1). As a result, adjust-
ment for BI-RADS density (Table 3) and percentage density
did not change BPU and breast cancer association (OR 3.3
[95 % CI 1.6–7.2] and OR 4.6 [95 % CI 2.1–10.5] for the
two readers). BPU was associated with BI-RADS density in
that the distribution of BPU categories differed across dens-
ity categories overall (p < 0.0001), and among cases for one
reader (reader 1, p = 0.04; reader 2, p = 0.10), and among
controls for both readers (p < 0.001), as shown Fig. 3.
Additional adjustment for family history or Gail model
5-year risk within the model that included BMI and BI-
RADS density adjustments had minimal impact on OR
estimates. When additional adjustment for family history
was made, the ORs for moderate or marked BPU vs.
photopenic or minimal to mild BPU were 3.3 (95 % CI
1.5–7.2) and 4.7 (95 % CI 2.1–10.6), whereas additional
adjustment for Gail model risk resulted in ORs of 3.5
(95 % CI 1.6–7.8) and 4.9 (95 % CI 2.1–11.5) for readers
1 and 2, respectively.
Moderate or marked BPU was more frequently
observed among premenopausal women (26 [51 %] of 51
to 28 [55 %] of 51 for the two readers, respectively) than
among postmenopausal women (25 [13 %] of 190 for both
readers, p < 0.001). As shown in Table 3, the association of
BPU with breast cancer remained in the postmenopausal
subgroup for both readers. In the premenopausal sub-
group, the association remained for reader 2 but did not
reach statistical significance for reader 1. Among post-
menopausal women, the results were unaffected with ad-
justment for use of hormone replacement therapy at the
Fig. 2 Example of incident breast cancer case. Right and left mediolateral oblique views are shown. In this 41-year-old premenopausal woman,
screening full-field digital mammography (a) was negative with Breast Imaging-Reporting and Data System density category of extremely dense.
Supplemental screening molecular breast imaging (MBI) (b) performed at the time of the screening mammogram showed marked background
parenchymal uptake. The next 2 years of screening mammography were negative. At 2.6 years after the initial MBI, the patient presented for diagnostic
workup of nipple retraction. (c) MBI performed at the time showed a lesion in the left breast (arrow) that was diagnosed as a 9-mm, grade I invasive
ductal carcinoma
Table 2 Association of four-category background parenchymal uptake at molecular breast imaging with breast cancer
BPU level Breast cancer casesa (n = 62) Controlsa (n = 179) ORb p-trend AUCb
Reader 1 0.007 0.62 (0.55–0.69)
Photopenic 5 (8) 26 (15) 0.8 (0.3–2.3)
Minimal to mild 35 (56) 124 (69) 1.0
Moderate 12 (19) 12 (7) 3.6 (1.4–8.9)
Marked 10 (16) 17 (9) 3.0 (1.1–8.4)
Reader 2 <0.001 0.63 (0.56–0.70)
Photopenic 2 (3) 18 (10) 0.5 (0.1–2.3)
Minimal to mild 36 (58) 132 (74) 1.0
Moderate 13 (21) 17 (9) 3.9 (1.6–9.7)
Marked 11 (18) 12 (7) 6.2 (2.0–19.0)
BPU background parenchymal uptake
aNumbers in parentheses are percentages
bNumbers in parentheses are 95 % CIs. OR is adjusted for body mass index
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time of MBI. Finally, there was an elevated risk for the
subset of cases and matched controls who had MBI with
the reduced-dose protocol in June 2009 or later compared
with those before June 2009 (OR 4.22 [95 % CI 1.55–
11.52] and OR 8.08 [95 % CI 2.41–27.07] for the two
readers), but there was no evidence for interaction (p =
0.28–0.45). The results were similar when we considered
BPU assessment from the contralateral vs. ipsilateral
breast for cancer cases and their respective matched con-
trols (Additional files 2: Table S2).
The ability to discriminate between cases and controls,
as assessed by the AUC, was 0.56 (95 % CI 0.48–0.63)
for a model including BMI and BI-RADS mammographic
density (age and menopausal status were matching vari-
ables). The addition of BPU to this model including BMI
and density resulted in AUCs of 0.64–0.67 (Table 3).
Table 3 Association of background parenchymal uptake with breast cancer by menopausal status
BPU Breast cancer
casesa
Controlsa OR adjusted for
BMIb
OR adjusted for BMI
and BI-RADS densityb




Photopenic or minimal to mild 40/62 (65) 150/179 (84) 1.0 1.0 1.0
Moderate or marked 22/62 (35) 29/179 (16) 3.4 (1.6–7.3) 3.3 (1.6–7.2) 3.6 (1.7–7.7)
p value 0.002 0.002 0.001
AUC 0.63 (0.56–0.70) 0.64 (0.57–0.71) 0.63 (0.56–0.70)
Reader 2
Photopenic or minimal to mild 38/62 (61) 150/179 (84) 1.0 1.0 1.0
Moderate or marked 24/62 (39) 29/179 (16) 4.8 (2.1–10.8) 4.6 (2.1–10.5) 5.0 (2.2–11.4)
p value <0.001 <0.001 <0.001
AUC 0.65 (0.58–0.72) 0.67 (0.60–0.74) 0.65 (0.58–0.72)
Premenopausal women
Reader 1
Photopenic or minimal to mild 4/13 (31) 21/38 (55) 1.0 1.0 NA
Moderate or marked 9/13 (69) 17/38 (45) 2.5 (0.6–10.0) 3.0 (0.7–6.8)
p value 0.18 0.14
AUC 0.63 (0.48–0.78) 0.63 (0.48–0.78)
Reader 2
Photopenic or minimal to mild 2/13 (15) 21/38 (55) 1.0 1.0 NA
Moderate or marked 11/13 (85) 17/38 (45) 9.4 (1.1–79.5) 10.2 (1.2–90.4)
p value 0.04 0.04
AUC 0.68 (0.54–0.83) 0.74 (0.60–0.87)
Postmenopausal women
Reader 1
Photopenic or minimal to mild 36/49 (73) 129/141 (91) 1.0 1.0 1.0
Moderate or marked 13/49 (27) 12/141 (9) 3.8 (1.5–9.3) 3.6 (1.5–9.0) 4.1 (1.6–10.3)
p value 0.004 0.006 0.003
AUC 0.64 (0.56–0.72) 0.65 (0.57–0.73) 0.63 (0.55–0.71)
Reader 2
Photopenic or minimal to mild 36/49 (73) 129/141 (91) 1.0 1.0 1.0
Moderate or marked 13/49 (27) 12/141 (9) 4.1 (1.6–10.2) 4.0 (1.6–9.9) 4.3 (1.7–10.9)
p value 0.002 0.003 0.002
AUC 0.65 (0.57–0.73) 0.66 (0.58–0.74) 0.64 (0.56–0.72)
BI-RADS Breast Imaging-Reporting and Data System, BMI body mass index, BPU background parenchymal uptake, HRT hormone replacement therapy, NA
not applicable
aNumbers in parentheses are percentages
bNumbers in parentheses are 95 % CIs
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Discussion
We present the first evidence for BPU on MBI as a risk
factor for breast cancer. The ORs of developing breast
cancer for women with moderate or marked BPU, com-
pared with those with photopenic or minimal to mild
BPU, were 3.4 and 4.8 for two readers, respectively. This
association was unaffected by adjustment for mammo-
graphic density measures. The association was also un-
affected by use of postmenopausal therapy and remained in
analysis limited to postmenopausal women only in order to
eliminate potential cyclic effects on BPU seen in premeno-
pausal women. The association between BPU and breast
cancer also remained in analysis limited to invasive breast
cancer cases only. Last, the association was similar in ana-
lyses performed using BPU assessed on the ipsilateral breast
vs. contralateral breast, suggesting that BPU is a general
marker of breast cancer risk rather than being specific to
the side of the eventual cancer.
The magnitude of the associations of breast cancer
risk with BPU found in this study are comparable to the
association of breast cancer with biopsy findings of atyp-
ical hyperplasia (relative risk 4.2) [23], noting the pos-
sible relevance for BPU information to be used in risk
stratification. As shown in this study and previous work,
BPU can vary substantially among women with similar
mammographic density [14], suggesting that BPU pro-
vides risk information beyond associations with density.
While mammographic density is established as an im-
portant breast cancer risk factor, a growing body of work
supports the existence of additional anatomical and func-
tional features of breast fibroglandular tissue that differ in
discriminatory capacity for predicting breast cancer risk.
For instance, extraction of breast density’s textural features
has shown potential to improve risk discrimination over
BI-RADS density categories and quantitative density as-
sessment [24–26]. In contrast to these mammographic
Fig. 3 Mosaic plots show distribution of background parenchymal uptake (BPU) categories on molecular breast imaging (MBI) as a function of Breast
Imaging-Reporting and Data System (BI-RADS) breast density categories for cases (a) and controls (b) interpreted by reader 1 and cases (c) and controls
(d) interpreted by reader 2. BI-RADS 1 = almost entirely fat; BI-RADS 2 = scattered fibroglandular densities; BI-RADS 3 = heterogeneously dense; BI-RADS
4 = extremely dense
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measures that depict fibroglandular tissue’s anatomical
appearance, BPU on MBI provides a functional measure
of Tc-99m sestamibi uptake, which is believed to be re-
lated to the presence of abundant mitochondria [27],
cellular proliferation, and likely blood flow and angio-
genesis as well [28].
Breast magnetic resonance (MR) imaging also depicts
functional behavior of breast lesions and benign fibro-
glandular tissue through gadolinium-based contrast en-
hancement, known as benign parenchymal enhancement
(BPE). Similar to our findings with BPU on MBI, BPE on
MR imaging is influenced by hormonal and reproductive
risk factors [29, 30] and has been associated with breast
cancer diagnosis in two studies with case-control designs,
reporting ORs of 3.3–10.1, though these studies were not
restricted to incident breast cancer cases [31, 32]. Similarly
to Tc-99m sestamibi, accumulation of gadolinium chelate
agents in breast tumors is related to angiogenesis and vas-
cular permeability [33]. One study has shown Tc-99m ses-
tamibi uptake and gadolinium enhancement in
background parenchyma to be correlated [34]. Several
studies have shown a lack of correlation between BPE and
mammographic density [35–37].
Within the Mayo Clinic practice, MBI is currently of-
fered to the population of women with mammographi-
cally dense breasts (BI-RADS density c or d) who seek
supplemental screening but do not meet criteria for
breast MR (>20 % lifetime risk by familial risk models)
[38]. Also, MBI is used for women in whom MR is rec-
ommended but cannot be performed due to contraindi-
cations, including inability or unwillingness to pay for an
MR examination.
Supplemental MBI screening in dense breasts has been
shown to offer a relatively high incremental cancer detec-
tion rate (8.8 cancers per 1000 women screened), a low
false-positive rate (18 % for mammography with supple-
mental MBI), and lower cost per cancer detected com-
pared with mammography alone [5, 39]. These factors,
coupled with ability to now perform MBI at radiation
doses acceptable for routine screening [40], support con-
tinued consideration of MBI as a suitable screening option
for women with dense breasts. In addition to the role of
MBI in supplemental screening, findings from this study
also support further investigation into whether MBI may
be useful as a risk prediction tool, especially if incorpo-
rated with other clinical risk predictors.
A strength of our study was the inclusion of only inci-
dent breast cancer cases, diagnosed at least 180 days
after index MBI. This study design allowed us to estab-
lish BPU as a risk factor for future development of
breast cancer, thus supporting the potential utility of
BPU in risk prediction. While a case-control study in-
cluding prevalent cases [31, 32] could identify factors
associated with a current breast cancer diagnosis, it
would not necessarily identify factors to be used in pre-
dicting subsequent risk. Further, by excluding cases at
the time of index MBI as well as patients with breast
cancer history who may have had noticeable treatment
effects, we avoided introducing potential bias into the
interpretation of BPU.
Our study had several limitations. First, BPU was
assessed as a subjective measure, which led to some dif-
ferences between the two readers. However, this subject-
ive measure represents how MBI is currently read in
practice, and the two readers agreed on BPU assessment
in 94 % of subjects.
A second potential limitation of our study was that we
did not have follow-up on approximately 6 % (183 of
3085) of patients in our MBI database from which the
breast cancer cases were selected. Therefore, it is pos-
sible that we could have missed some breast cancers di-
agnosed outside our institution. However, we matched
on known follow-up time, so our controls represented
our cases and we do not anticipate a systematic bias.
Finally, the study data lacked specific information on day
of menstrual cycle at which MBI was performed among
premenopausal women. In a prior cross-sectional analysis
including 417 premenopausal or perimenopausal women,
no association between BPU category and follicular vs. lu-
teal phase was found (p = 0.65) [14]. However, in a subse-
quent study of 42 premenopausal women with regular
menstrual cycles, serial MBIs were timed to be performed
at peak follicular and luteal phases. Within-woman analyses
showed high BPU (moderate or marked) to be observed
more frequently at luteal phase than follicular phase [15]. It
is currently unclear whether menstrual cycle effects on
BPU have associations with breast cancer risk. However,
our finding of a strong association between breast cancer
and BPU in the postmenopausal subgroup, even after ad-
justment for hormone therapy, suggests that the association
of BPU with breast cancer is not simply an artifact of pre-
menopausal cyclic variation in BPU.
Our study included primarily women with mammo-
graphically dense breasts (80 % were either heteroge-
neously or extremely dense). The low number of women
with nondense breasts likely accounts for the lack of a
statistically significant association between mammographic
density measures and breast cancer observed in this
population. However, since this population is the target
subgroup that would receive MBI, it is appropriate for
our investigation.
Conclusions
BPU, which describes the functional uptake observed
within fibroglandular tissue on MBI, is strongly associated
with breast cancer risk, and this association remained after
adjustments for mammographic density or postmenopausal
hormone use. For women with dense breasts, who
Hruska et al. Breast Cancer Research  (2016) 18:42 Page 9 of 11
comprise over 40 % of the screening-eligible population,
BPU may serve as an additional risk factor to help identify
the subgroup most likely to benefit from tailored screening
or primary prevention options.
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